Effect and safety of mesenchymal stem cells for patients with COVID-19: systematic review and meta-analysis with trial sequential analysis.

Based on the pooled results in this study, compared with standard treatment, MSCs therapy may reduce all-cause mortality of patients with COVID-19 with no increase risk of AEs and sAEs, but may not improve symptom remission rate. Further more high-quality and large-sample RCTs should be performed to confirm these findings. This article is protected by copyright. All rights reserved.